Literature DB >> 10195613

Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine.

I Stefano1, H K Sato, C S Pannuti, T M Omoto, G Mann, M S Freire, A M Yamamura, P F Vasconcelos, G W Oselka, L W Weckx, M F Salgado, L F Noale, V A Souza.   

Abstract

In order to determine whether previous measles vaccination interferes with the sero-response to yellow fever vaccine, 294 children at nine months of age were randomly assigned to immunization with yellow fever vaccine at different time intervals after measles vaccination. The seroconversion rate (SCR) and the log10 geometric mean titer (GMT) for 17 DD yellow fever vaccine at different intervals after Schwarz measles vaccination were: 1-6 days: SCR = 44/57 = 77%; GMT = 4.57; 7-13 days: SCR = 36/53 = 68%; GMT = 4.46; 14-21 days: SCR = 55/65 = 85%; GMT = 4.46; 22-27 days: SCR = 41/54 = 76%; GMT = 4.41 and >28 days: SCR = 52/65 = 80%; GMT = 4.24 (p > 0.05). We conclude that recent immunization against measles does not interfere with the sero-response to yellow fever vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195613     DOI: 10.1016/s0264-410x(98)00320-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Lack of interference by zoster vaccine with the immune response to yellow fever vaccine.

Authors:  David M Stier; Ingrid B Weber; J Erin Staples
Journal:  J Travel Med       Date:  2012-02-28       Impact factor: 8.490

2.  Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Authors:  Myrna C Bonaldo; Richard C Garratt; Renato S Marchevsky; Evandro S F Coutinho; Alfredo V Jabor; Luís F C Almeida; Anna M Y Yamamura; Adriana S Duarte; Prisciliana J Oliveira; Jackeline O P Lizeu; Luiz A B Camacho; Marcos S Freire; Ricardo Galler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

4.  Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.

Authors:  Marlon G Veloso de Santana; Patrícia C C Neves; Juliana Ribeiro dos Santos; Noemia S Lima; Alexandre A C dos Santos; David I Watkins; Ricardo Galler; Myrna C Bonaldo
Journal:  Virology       Date:  2014-02-08       Impact factor: 3.616

5.  Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.

Authors:  Constantina Boikos; Jesse Papenburg; Christine Martineau; Lawrence Joseph; David Scheifele; Mark Chilvers; Larry C Lands; Gaston De Serres; Caroline Quach
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

Review 6.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

7.  Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo.

Authors:  Alexandra C Willcox; Matthew H Collins; Ramesh Jadi; Corinna Keeler; Jonathan B Parr; Dieudonné Mumba; Melchior Kashamuka; Antoinette Tshefu; Aravinda M de Silva; Steven R Meshnick
Journal:  Am J Trop Med Hyg       Date:  2018-07-05       Impact factor: 2.345

8.  A High-Throughput Yellow Fever Neutralization Assay.

Authors:  Madina Rasulova; Thomas Vercruysse; Jasmine Paulissen; Catherina Coun; Vanessa Suin; Leo Heyndrickx; Ji Ma; Katrien Geerts; Jolien Timmermans; Niraj Mishra; Li-Hsin Li; Dieudonné Buh Kum; Lotte Coelmont; Steven Van Gucht; Hadi Karimzadeh; Julia Thorn-Seshold; Simon Rothenfußer; Kevin K Ariën; Johan Neyts; Kai Dallmeier; Hendrik Jan Thibaut
Journal:  Microbiol Spectr       Date:  2022-06-07

9.  DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Authors:  Adriana S Azevedo; Anna M Y Yamamura; Marcos S Freire; Gisela F Trindade; Myrna Bonaldo; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

10.  17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.

Authors:  Ana Carolina Campi-Azevedo; Luiza Pacheco de Araújo-Porto; Maria Luiza-Silva; Maurício Azevedo Batista; Marina Angela Martins; Renato Sathler-Avelar; Denise da Silveira-Lemos; Luiz Antonio Bastos Camacho; Reinaldo de Menezes Martins; Maria de Lourdes de Sousa Maia; Roberto Henrique Guedes Farias; Marcos da Silva Freire; Ricardo Galler; Akira Homma; José Geraldo Leite Ribeiro; Jandira Aparecida Campos Lemos; Maria Auxiliadora-Martins; Iramaya Rodrigues Caldas; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.